|Bid||64.15 x 200|
|Ask||65.24 x 500|
|Day's Range||63.00 - 65.29|
|52 Week Range||36.40 - 99.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2018 - Feb 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||89.73|
Clovis Oncology shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.
Clovis rose Wednesday to the detriment of Tesaro and AstraZeneca after the FDA accepted its application for expanded use of its PARP inhibitor known as Rubraca.
The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients. The Boulder-based company (CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA says it will make a decision by April 6, 2018, Clovis announced Tuesday.
Clovis Oncology announced today that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application for rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act date of April 6, 2018.
After a very strong year, the biotech sector has suffered an 8% pullback over the past 5 weeks. Todd Hagopian, whose biotech portfolio is up 38% this year, believes that the recent pullback has created bargains in Alexion, Flexion, Clovis, Tesaro, and Incyte.
Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $2.97 billion over the last one-month into ETFs that hold CLVS are not among the highest of the last year and have been slowing.
Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.
NEW YORK, NY / ACCESSWIRE / November 20, 2017 / U.S. markets closed in the red Friday, with the Dow Jones and S&P 500 posting their second consecutive weekly loss, as concerns regarding President Trump's ...
Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding CLVS are favorable, with net inflows of $3.51 billion.
NEW YORK, Nov. 14, 2017-- In a release issued under the same headline on November 13th, 2017 by Fundamental Markets, please note that in the P ure Storage's Recent Financial Performance section, the first ...
NEW YORK, Nov. 13, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pure ...
Clovis Oncology, Inc. today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 9:30 AM Eastern Time.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Clovis Oncology, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Research Desk Line-up: Clovis Oncology Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
Clovis Oncology, Inc. reported financial results for the quarter ended September 30, 2017, and provided an update on the Company’s clinical development programs and regulatory outlook for the remainder of 2017.
NEW YORK, NY / ACCESSWIRE / November 1, 2017 / Clovis Oncology, Inc. (NASDAQ: CLVS ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 1, 2017 at 4:30 PM Eastern ...
Clovis Oncology, Inc. will announce its third quarter 2017 financial results on Wednesday, November 1, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m.